Repare Therapeutics Inc. (RPTX) on Wednesday said it has reached an agreement with Gilead Sciences, Inc. to transfer its Pol? ATPase inhibitor, RP-3467, in a deal worth up to $30 million. Following the announcement, the company's shares rose more than 20% in pre-market trading.The consideration includes a $25 million upfront payment and an additional $5 million payment upon completion of specified transfer activities.RP-3467 is currently being evaluated in a Phase 1 study, both as a monotherapy and in comb ...